The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Impact of Duffy status on PFS in newly diagnosed multiple myeloma treated with RVd ± autoSCT
In this video, Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, presents the findings of an updated subgroup analysis of the Phase III DETERMINATION trial (NCT01208662) exploring the impact of Duffy status on progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (MM) treated with lenalidomide, bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (autoSCT) and continuous R maintenance. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
